Page 1

Press release Ad hoc announcement pursuant to Art . 53 LR Galenica Date Contact Subject 22 October 2026 Investor Relations : investors@galenica.com/+41 58 852 85 31 Media Relations : media@galenica.com/ +41 58 852 85 17 Galenica Group Sales January - September 2026 Galenica continues growth trajectory and confirms outlook for 2026 • • • • Galenica increases sales by 5.7 % to CHF 3,172.0 million in the first nine months of 2026 . The pharmacy business and home care are key contributors to growth . Diagnostics continues to perform positively . Galexis successfully completes a comprehensive modernisation of its IT systems . Galenica confirms its outlook for the 2026 financial year . Galenica continued its growth trajectory in the first nine months of 2026 and increased sales by 5.7 % to CHF 3,172.0 million . The main drivers were the continued positive performance in the pharmacy business , strong growth in the home care sector and the integration of the Diagnostics business segment . Temporary restrictions on the product range during the ERP migration resulted in weaker growth in the wholesale business in the third quarter . Julian Fiessinger , CFO of Galenica , sums up the sales result : " We continued our growth trajectory in the high - margin Products & Care segment in the third quarter . The good performance of our pharmacy business and the strong growth in the home care sector are particularly pleasing . Following the successful ERP switchover , we also expect to see higher growth momentum again in wholesale in the fourth quarter . We are therefore still on track to achieve our guidance . " Pharmacy business continues to develop positively The Pharmacies Omni - channel business segment continued its positive development , increasing net sales by 6.2 % to CHF 1,134.5 million , with organic growth of 4.5 % . Sustained strong demand for prescription - only medication once again proved to be a growth driver . These include , in particular , GLP - 1 - based weight loss products and medications for the treatment of rheumatic diseases . Taking into account the product mix ( Rx and OTC products : + 5.3 % ² , non - drugs segment in the consumer healthcare market : + 1.1 % ³ ) , this results in further market share gains for Galenica pharmacies . Demand for fee - based advisory and healthcare services also continued to increase : Around 290,000 such services were provided in the first nine months ( + 26 % ) , including 34,000 vaccinations . Consumer healthcare market remains competitive The Products & Brands business segment generated net sales of CHF 136.5 million ( -7.2 % ) , driven in particular by seasonal factors as well as adverse one - off effects in the international business . Due to the portfolio's focus on flu and cold products , market sales of Verfora products declined Galenica Ltd. Untermattweg 8 | P.O. Box | CH - 3001 Bern +41 58 852 81 11 | info@galenica.com | galenica.com Galenica - Health and well - being are at the heart of what we do .